Stocks · News reference

Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

Aug 7, 2026, 1:27 PMBenzinga Newsdesk

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 7, 2026, 8:25 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.
Read original at benzinga
VRDN
BenzingaAug 6, 2026, 7:50 PMBenzinga Newsdesk
Viridian Therapeutics shares are trading higher after the company reported better-than-expected Q2 sales results.
Read original at benzinga
VRDN
BenzingaAug 6, 2026, 11:50 AMBenzinga Newsdesk
Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K Estimate
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 5 percent decrease over losses of $(1.00) per share
Read original at benzinga
VRDN